Codon-optimized GALC gene, adeno-associated virus and application

By codon optimization of GALC gene and binding with AAV vector, the problem of insufficient GALC gene expression level in AAV gene therapy was solved, significantly improving the survival and treatment effect of Crabbe disease model mice, reducing side effects and treatment costs.

CN119082155APending Publication Date: 2024-12-06CHINA THREE GORGES UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411211283.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing AAV gene therapy has limited effect on the survival prolongation of mice in Crabbe disease model, mainly because the expression level of AAV vector mediated by the lack of high enough GALC gene expression, resulting in limited therapeutic effects and side effects.

Method used

The GALC gene was optimized by codons to improve its expression level, and the optimized GALC gene was combined with recombinant adeno-associated viral vectors to construct the pAAV-CBA-GALC-OPT-Flag recombination plasmid and AAV5-CBA-GALC-OPT-Flag recombination Virus significantly improves GALC activity and reduces therapeutic dose requirements and side effects.

Benefits of technology

It improves the expression level of GALC protein, enhances the therapeutic effect, prolongs the survival of mice in Crabbe disease model, reduces the cost of treatment and side effects, and provides a more lasting therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082155A_ABST
    Figure CN119082155A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a codon-optimized GALC gene and an adeno-associated virus, belongs to the field of gene engineering, and designs the codon-optimized GALC gene, the sequence of which is SEQ ID NO: 2, and the codon-optimized GALC gene has 76% homology with a wild type GALC gene segment as shown in SEQ ID NO: 1. The expression of the codon-optimized GALC gene in cells is obviously superior to that of a wild type GALC gene, so that the dosage of GALC gene therapeutic drugs can be relatively reduced, and the drug cost is reduced. Meanwhile, the invention further provides a recombinant adeno-associated virus carrying the codon-optimized GALC gene, and the recombinant adeno-associated virus can be used for preparing a medicine for treating the Kraber disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of genetic engineering technology and specifically relates to a codon optimized GALC Genes and adeno-associated viruses and their applications. Background Art

[0002] Globoid cell leukodystrophy, also known as Krabbe disease, is a hereditary disease caused by GALC It is caused by gene mutation. In 1916, Danish neurologist Knud Krabbe first described the disease in detail, so the disease was named after him. The main feature of Krabbe disease is the deficiency of galactosylceramidase (GALC), which is responsible for the decomposition of galactosylceramidase, galactosylceramide and galactosylsphingosine in the normal myelin phospholipid metabolism process, producing metabolites such as sphingosine and ceramide that are essential for the synthesis and maintenance of myelin. GALC deficiency causes galactosylsphingosine and galactosylceramide to accumulate in cells, forming spherical cells in the central nervous system, and causing nerve demyelination and severe neurological diseases in the tissue cells of the peripheral nervous system.

[0003] Krabbe disease is usually diagnosed in infancy. If not treated promptly, patients may die within 2 to 3 years due to severe demyelination and organ failure. Common symptoms include irritability, paralysis, blindness, hearing loss and epileptic seizures. Currently, the only clinical treatment for Krabbe disease is hematopoietic stem cell transplantation, but this method can only partially slow the progression of Krabbe disease and still cannot cure the disease. In addition, the transplantation surgery must be performed before the patient develops symptoms, and after hematopoietic stem cell transplantation, patients will still experience progressive neurological degeneration and reduced quality of life. Therefore, the development of new treatments is urgent.

[0004] In recent years, a variety of therapeutic strategies have been developed in Krabbe disease model mice, including virus-mediated gene therapy, GALC enzyme replacement therapy, substrate reduction therapy, and anti-inflammatory therapy. GALC The method of replacing mutant genes with genes has attracted widespread attention because it directly targets the genetic root of the disease. Initial gene therapy mainly used retroviral vectors and adenoviral vectors, but these vectors may bring high tumorigenicity and immunotoxicity and are not suitable for clinical application. In contrast, recombinant adeno-associated virus has become the preferred vector for the treatment of single-gene genetic diseases due to its high in vivo transduction efficiency, low immunogenicity and good clinical safety.

[0005] As early as 2005, the Sands and Wenger research groups published a study on Krabbe gene therapy using AAV as a vector. So far, a variety of different AAV serotypes have been tested in the Twitcher mouse model. The results showed that regardless of the AAV serotype, the median life span after gene therapy only increased from 40 days to about 70 days, and the dose of AAV virus and the survival of mice had a dose-dependent relationship within a certain range. In short, AAV gene therapy has a very limited effect on extending the survival of Krabbe model mice. The main reason is that AAV vectors mediate GALC This is closely related to the low expression level of the gene, which is also one of the main reasons why the research on Krabbe gene therapy was carried out early, but so far no Krabbe gene therapy drug has been approved for marketing.

[0006] In gene therapy, it is crucial to improve the expression yield of the delivered gene. Codon optimization is a genetic engineering technique that can increase the expression level of a specific protein by modifying the codons in the DNA or mRNA sequence without changing the amino acid sequence of the protein. GALC Codon optimization improves GALC protein expression level, which has the following advantages: Enhanced therapeutic effect: high levels of GALC Gene expression can more effectively replenish dysfunctional proteins, thereby improving or reversing disease symptoms.

[0007] Reduced therapeutic dose requirements: by increasing GALC The level of gene expression can reduce the required dose of viral vector. This can not only reduce production costs, but also reduce the total amount of viral vector in the patient's body, thereby reducing potential immune responses and side effects.

[0008] Improved durability of treatment: By increasing gene expression levels, the number of times treatment needs to be repeated is reduced. This means less inconvenience for patients and lower treatment costs.

[0009] Reducing side effects: by optimizing GALC Gene expression levels can allow the use of lower viral vector doses without sacrificing therapeutic efficacy, thereby reducing immune responses and other potential side effects.

[0010] The invention aims to overcome the problems in the prior art due to GALC The defects and deficiencies of the treatment strategy for Krabbe disease caused by gene mutations are addressed by providing a codon-optimized GALC Gene, the present invention achieves GALCThe invention can achieve a higher expression level of the gene. This improvement will significantly reduce the dosage of the drug required for Krabbe disease treatment, thereby optimizing the treatment plan. In addition, the invention also introduces a method for preparing a gene therapy drug for Krabbe disease using an AAV vector, which provides a new approach for the effective treatment of Krabbe disease. In summary, the invention has important clinical significance and transformation application value. Summary of the invention

[0011] In view of the above technical problems, the present invention provides a codon-optimized GALC Gene and carrier codon optimization GALC Adeno-associated virus and its application.

[0012] In order to achieve the above object, the present invention provides a codon-optimized GALC Gene, GALC The sequence of the gene is SEQ ID NO:2.

[0013] Preferably, the sequence consistency comparison is performed by DNAMAN software, and the sequence optimization GALC Gene and wild type GALC The gene sequence has 76% homology; the wild type GALC The gene sequence is SEQ ID NO:1.

[0014] The present invention also provides a codon-optimized GALC The application of genes in the preparation of drugs for the treatment of Krabbe disease.

[0015] The present invention also provides a codon-optimized GALC Recombinant adeno-associated virus expression vectors for genes, including codon-optimized GALC Gene and adeno-associated virus expression vector containing CBA promoter.

[0016] Preferably, the sequence of the adeno-associated virus expression vector pAAV-CBA-GALC-OPT-Flag is SEQ ID NO: 3, and the codon optimized GALC The gene sequence is SEQ ID NO:2.

[0017] Further preferably, the adeno-associated virus capsid expression plasmid is any one of pAAV1, pAAV2, pAAV5, pAAV9 and pAAV10.

[0018] The present invention also provides a codon-optimized GALC A method for constructing a recombinant adeno-associated virus expression vector of a gene comprises the following steps: (1) Yes GALCThe gene was codon optimized, and a Flag linker was added to the 3' end. After synthesis, the 5' and 3' ends were added with protective bases and BamH I / Xho I restriction sites, respectively, to obtain the GALC-OPT-Flag gene fragment; (2) The GALC-OPT-Flag gene fragment and the pAAV-CBA-LUC plasmid were double-digested, recovered and purified, and then ligated with T4 DNA ligase to obtain a ligation product; (3) The ligation product was transformed into Escherichia coli. After overnight culture, a single clone was picked out for amplification and plasmid extraction for detection to obtain the recombinant adeno-associated virus expression vector pAAV-CBA-GALC-OPT-Flag.

[0019] Preferably, the restriction endonucleases used in the double digestion in step (2) are BamH I and Xho I, and the digestion conditions are 37° C. for 2 h; Preferably, the connection condition in step (3) is 16° C. for 16 h.

[0020] The present invention also provides a codon-optimized GALC The invention discloses a recombinant adeno-associated virus expressing a gene, wherein the recombinant adeno-associated virus comprises an AAV capsid, an AAV genome packaged in the AAV capsid, a CBA promoter, and a codon-optimized GALC gene sequence; the codon-optimized GALC gene sequence is SEQ ID NO: 2, and has 76% homology with the wild-type GALC gene fragment shown in SEQ ID NO: 1.

[0021] The present invention also provides a codon-optimized GALC A method for preparing a recombinant adeno-associated virus containing a gene, the preparation method comprising a packaging method and a purification method, wherein the packaging method is to co-transfect HEK293T cells with pAAV-CBA-GALC-OPT-Flag, pHelper, and pAAV9 using a three-plasmid packaging system, and collect the supernatant and cells after transfection for purification; The purification method is to use iodixanol density gradient centrifugation to purify.

[0022] The present invention also provides a codon-optimized GALC Application of recombinant adeno-associated virus with a gene in the preparation of drugs for treating Krabbe disease.

[0023] The beneficial effects of the present invention are: 1. Provides a codon-optimized GALC gene, which is different from wild type GALC The genes maintain high homology and show higher protein expression efficiency.

[0024] 2. By optimizing the GALC By recombining the gene with an adeno-associated virus expression vector, we successfully constructed the pAAV-CBA-GALC-OPT-Flag recombinant plasmid, and further packaged and purified it to obtain the AAV5-CBA-GALC-OPT-Flag recombinant virus. This recombinant virus can significantly increase the GALC activity of neural stem cells in GLD brain organoids and effectively reduce the concentration of psychosine. This feature is not only conducive to reducing the dose required for treatment, enhancing the therapeutic effect, improving the durability of treatment, and reducing side effects, but also has the potential to significantly reduce the cost of gene therapy drugs for Krabbe disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 The gel electrophoresis results of the recombinant plasmids pAAV-CBA-GALC-WT-Flag and pAAV-CBA-GALC-OPT-Flag in Example 1, where M is the Gene Ruler 1kb DNA Ladder, 1 is pAAV-CBA-GALC-WT-Flag, and 2 is pAAV-CBA-GALC-OPT-Flag.

[0026] Figure 2 This is a schematic diagram of the expression cassette of the recombinant plasmid pAAV-CBA-GALC-OPT-Flag in Example 1.

[0027] Figure 3 The results of Western Blot in Example 2 are shown in Figure A, which is a protein blot and Figure B is a bar graph showing quantitative differences in GALC protein.

[0028] Figure 4 This is the fluorescence expression image of TUJ1 and NeuN in the neuronal cell model in Example 6.

[0029] Figure 5 This is the activity bar graph of GALC in Example 7.

[0030] Figure 6 This is a bar graph showing the concentration of Psychosime in Example 8. DETAILED DESCRIPTION

[0031] The technical solution of the present invention is further explained below in conjunction with the accompanying drawings and specific embodiments. It is worth noting that the following embodiments are only preferred embodiments of the present invention and should not be understood as limiting the present invention. The protection scope of the present invention shall be based on the contents recorded in the claims. Any modification or replacement made by those skilled in the art to the technical solution of the present invention without creative work shall fall within the protection scope of the present invention.

[0032] Commonly used cells, plasmids and reagents: pAAV-CBA-LUC vector plasmid: preserved by Hubei Key Laboratory of Tumor Immunity and Microenvironment; Competent cells Trans1-T1: purchased from Nanjing Novozymes Biotech Co., Ltd.; HEK 293T cells: maintained by Hubei Key Laboratory of Tumor Immunity and Microenvironment; pAAV9 plasmid: kindly donated by Professor Zhang Ye of Peking Union Medical College; pHelper plasmid: kindly donated by Professor Zhang Ye of Peking Union Medical College; ssAAV-eGFP standard plasmid: kindly donated by Professor Zhang Ye of Peking Union Medical College; iPSC cells: provided by China-Japan Friendship Hospital; BamH I, Xho I: purchased from Bio-Bio Technology Co., Ltd.; T4 DNA ligase: purchased from Biobiotech Co., Ltd.; Anti-Flag antibody: purchased from Sewell Biotechnology Co., Ltd.; Anti-β-actin: purchased from Sewell Biotechnology Co., Ltd.; Goat anti-mouse IgG: purchased from Biobio Technology Co., Ltd.; Anti-Tuj1 antibody: purchased from Biolegend; Anti-NeuN antibody: purchased from proteintech; Anti-Rabbit Alexa Fluor 594 antibody: purchased from Thermo Fisher Scientific; Anti-Mouse Alexa Fluor 488 antibody: purchased from Thermo Fisher Scientific; 5% TBST buffer solution: Tris-HCL (1M, pH 7.5) 50 mL, NaCl 8 g, KCl 0.2 g, Tween 0.5 mL, add distilled water to make up to 1 L; Transfection reagent Cytokey: purchased from Nanjing Zhongji Dangkang Biotechnology Co., Ltd.; Universal nuclease: purchased from Yisheng Biotechnology Co., Ltd.; Iodixanol (iodix):

[0033] mTeSR1 medium: purchased from Stem cell company; ReLeSR: purchased from Stem cell company; 4% PFA: purchased from Sewell Biotechnology Co., Ltd.; Trypan blue staining solution: Mix PBST and 0.4% trypan blue solution at a volume ratio of 1:50; 1% BSA: Dissolve 1 g BSA in 100 mL of 5% TBST solution and stir thoroughly to dissolve; DAPI stain: purchased from Sigma; MarkerGeneTM Lysosomal Galactocerebrosidase Assay Kit (M2774): purchased from abcam; D-erythro-Sphingosine (123-78-4): purchased from MCE; Galactosylsphingosine: purchased from MCE; Example 1 Construction of recombinant plasmid (1) Download human genome from NCBI GALC The gene CDS region sequence, the sequence is SEQ ID NO: 1, and the Flag tag sequence is added to its 3' end, named GALC-WT-Flag, and synthesized in Wuhan Bioengineering Co., Ltd.; (2) Yes GALC Genes are codon optimized and the species is optimized for humans ( Homo sapiens ), the factors adjusted include but are not limited to the following: adjusting the codon usage bias to adapt to the highest expression profile of the target host; CAI (codon adaptation index) upgraded from 0.73 to 0.97; the average GC content was adjusted from 45.9% to 60.2%, and unfavorable peaks were removed; the entire sequence was fine-tuned to improve translation efficiency and extend the half-life of mRNA, etc. The optimized sequence is SEQ ID NO: 2, and then a Flag tag sequence is added to its 3' end, and then named GALC-OPT-Flag; (3) GALC-WT-Flag fragment and GALC-OPT-Flag fragment were synthesized by Sangon Biotechnology Co., Ltd., with BamH I and Xho I restriction sites at both ends of the synthetic fragments. GALC-WT-Flag, GALC-OPT-Flag and pAAV-CBA-LUC vector plasmids were double-digested with BamH I and Xho I at 37°C, respectively. The restriction enzyme digestion system is shown in Table 1; Table 1 Double enzyme digestion system

[0034] (4) After 2 hours of double digestion, the digestion products were obtained. 3 μL was taken for electrophoresis to confirm the success of the digestion. Then the remaining digestion products were loaded and electrophoresed at 98V for 40 minutes to separate the DNA fragments. Then, the DNA fragments were purified using a gel recovery kit to obtain purified GALC-WT-Flag fragments, purified GALC-OPT-Flag fragments, and purified AAV vector plasmids. (5) Use T4 DNA ligase to mix the purified GALC-WT-Flag fragment and the purified GALC-OPT-Flag fragment with the purified AAV vector plasmid respectively, and connect them at 16°C for 16 hours to obtain the ligation product. The ligation system is shown in Table 2: Table 2 Connection system

[0035] (6) All ligation products were transferred into competent cells Trans1-T1. After culturing at 37°C overnight, single clones were picked for amplification. After plasmid extraction, agarose gel electrophoresis analysis was performed. The results were as follows: Figure 1 As shown: Clear electrophoresis bands can be detected for both recombinant plasmids pAAV-CBA-GALC-WT-Flag and pAAV-CBA-GALC-OPT-Flag, and the plasmid size is about 5500bp, which is consistent with expectations. Sanger sequencing was performed on the two recombinant plasmids containing GALC-WT and GALC-OPT. The sequencing results showed that two recombinant plasmids containing GALC-WT and GALC-OPT were successfully constructed, among which the expression cassette of pAAV-CBA-GALC-OPT-Flag is as follows Figure 2 shown.

[0036] Example 2 Western Blot Detection The cells were transfected with the pAAV-CBA-GALC-WT-Flag recombinant plasmid (GALC-WT group) and the pAAV-CBA-GALC-OPT-Flag recombinant plasmid (GALC-OPT group) constructed in Example 1, and the cells were transfected with the pAAV-CBA-GFP plasmid as the mock group. Then, proteins were extracted for Western Blot detection. The specific method is as follows: (1) The above three recombinant plasmids were transfected into HEK 293T cells respectively. After 48 h of culture, the supernatant was discarded, RIPA lysis buffer was added to extract cell protein, and the protein was quantified by BCA method; (2) Take 20 μg of protein sample, separate it by 10% SDS-PAGE, transfer it to PVDF membrane at 300 mA constant current, and block the PVDF membrane with 5% skim milk at room temperature for 1 h; (3) The primary antibodies (anti-Flag, anti-β-actin) were incubated at 4°C overnight, and the secondary antibodies (goat anti-mouse IgG) were incubated at room temperature for 1 h, followed by rinsing with TBST three times. The substrate reaction solution was added dropwise for 2 min, and the ECL method was used for color development. The protein expression level was determined based on the color development results.

[0037] like Figure 3 As shown, the target band was successfully displayed at 75kD using anti-Flag ( Figure 3 A, and the quantitative difference of GALC protein was analyzed by Image J software. The results showed that the expression level of GALC protein in the GALC-OPT group was higher, which was significantly different from that in the GALC-WT group, indicating that the sequence after codon optimization can better express GALC protein ( Figure 3 B).

[0038] Example 3 Virus packaging and purification Taking the preparation of AAV9-CBA-GALC-OPT-Flag virus as an example, the virus was packaged using a three-plasmid packaging system, and then purified using iodixanol density gradient centrifugation. The specific method is as follows: (1) Cell transfection: HEK 293T cells were cultured to a density of approximately 90% and the medium was changed 2 hours before transfection; (2) Prepare the solutions required for transfection: Solution A: pAAV9 plasmid, pAAV-CBA-GALC-OPT-Flag recombinant plasmid and pHelper plasmid are mixed in serum-free and anti-dual antibody-free DMEM medium at the amount of 8 μg, 6 μg and 10 μg respectively; Solution B: Transfection reagent Cytokey is diluted in serum-free and anti-dual antibody-free DMEM medium at the ratio of 1 μL DMEM medium for every 2 μg plasmid; (3) After standing at room temperature for 4 minutes, add solution A dropwise into solution B and mix gently. After standing at room temperature for 20 minutes, add the AB mixture evenly and slowly into the cultured cells. Replace the culture medium 4 hours after transfection and continue culturing for 48 hours. (4) Virus collection: Collect the cell pellet and supernatant that produce the virus in a 50 mL centrifuge tube. After centrifugation, harvest the culture medium supernatant and cell pellet separately: add PEG8000 to the supernatant and centrifuge at 3000 r for 2 h, discard the supernatant, and resuspend in PBS; freeze and thaw the cell pellet three times, add 50 U / mL universal nuclease, digest at 37 °C for 1 h, centrifuge at 10000 × g for 10 min, and take the supernatant. Combine the AAV9-CBA-GALC-OPT-Flag obtained from the cell pellet and supernatant; (5) Virus purification: Use iodix density gradient centrifugation to purify adeno-associated virus. Add 9 mL of 15% iodix / 1M NaCl, 6 mL of 25% iodix, 6 mL of 40% iodix, and 3 mL of 60% iodix to the ultracentrifuge tube in sequence. Finally, add the virus to the top layer and fill it with PBS. (6) Use an ultra-high refrigerated speed centrifuge to centrifuge the ultracentrifuge tube obtained in step (5) at 60,000 r and 4°C for 2 h 30 min. After centrifugation, different concentrations of iodixanol can be seen in distinct colors. The AAV virus is located in the colorless 40% iodixanol layer. After being aspirated with a syringe, the virus is ultrafiltered and concentrated using an ultrafiltration centrifuge tube with a molecular weight cutoff of 100 KD. The virus is collected in an EP tube to obtain the AAV9-CBA-GALC-OPT-Flag virus, which is stored at -80°C for later use.

[0039] AAV9-CBA-GALC-WT-Flag virus was also packaged and purified according to the above method.

[0040] Example 4 qPCR detection of virus titer Using ssAAV-eGFP as the standard plasmid, gradient dilution was performed, and then qPCR reaction was performed to draw the curve. By comparing with the Ct value, the number of viral copies contained in the recombinant virus was obtained, and the viral titer was calculated. The specific steps are as follows: (1) The standard plasmid ssAAV-eGFP was serially diluted to 10 µg / µL, 1 µg / µL, 0.1 µg / µL, 0.01 µg / µL, and 0.001 µg / µL; (2) Designing universal primers for the ITR region of the AAV virus, wherein the sequence of the upstream primer is SEQ ID NO: 4 and the sequence of the downstream primer is SEQ ID NO: 5; (3) qPCR experiments were performed on the AAV9-CBA-GALC-OPT-Flag recombinant virus and standard plasmids of different concentrations. The qPCR reaction system is shown in Table 3. The reaction procedure is as follows: pre-denaturation at 95°C for 3 min; denaturation at 95°C for 10 s, annealing at 60°C for 30 s, and end point reading, for a total of 39 cycles; the melting curve is between 65°C and 95°C; end; Table 3 qPCR reaction system

[0041] (4) The copy number of 1 µg of standard plasmid ssAAV-eGFP is 2×10 8The lg value of the copy number was taken as the X-axis and the Ct value obtained by qPCR detection was taken as the Y-axis to establish a standard curve and calculate the AAV-CBA-GALC-OPT-Flag virus titer, which was 3.3×10 9 vg / uL.

[0042] Example 5 Construction of Krabbe disease neuronal model China-Japan Friendship Hospital collected skin tissue from Krabbe patients and isolated skin fibroblasts. In 2020, the skin fibroblasts of Krabbe patients were reprogrammed into iPSCs for the first time (see Wang, W., YF Lv, YJ Zhang, WJ Dong, Y. Zhang. Generation of a human induced pluripotent stem cell line PUMCi001-A from a patient with Krabbe disease. Stem Cell Res, 2020. 48: p.101937.). iPSCs derived from Krabbe patients were used as initial cells and induced to differentiate into neurons, thereby establishing a neuronal cell model of Krabbe disease. The therapeutic effect of AAV-mediated codon-optimized GALC was verified in this model. The construction process of the neuronal cell model is as follows: (1) Culture on Matrigel-coated plates containing mTeSR1 medium at 37°C and 5% CO2. Subculture the cells every 4 days using ReLeSR until they are in good condition and the cell differentiation rate is <10%. (2) The second day after iPSCs division is recorded as the first day of neural stem cell induction. Observe the cells. At this time, the cell density is about 15-25%. Replace the iPSCs culture medium with neural stem cell induction medium (Neurobasal medium 490 mL, Gibco neural induction culture supplement 10 mL), and place the cells back into the CO2 incubator for continued culture. (3) On the second day of induction, replace the neural stem cell induction medium, and then replace the medium every other day. Cell fusion may occur around the fourth day of induction. If the cell density is high, the number of cell medium changes can be appropriately increased to ensure cell nutrition until the seventh day of cell induction; (4) After the induction of neural stem cells is completed, the cells are digested with StemPro™ Accutase™, resuspended in DPBS, and transferred to a 15 mL centrifuge tube; (5) Centrifuge at 800 rpm for 5 min and discard the supernatant; (6) Take 2 mL of neuronal differentiation medium to resuspend the cells and take a small amount of cells to count; (7) According to the cell counting results, 5×10 5 The cells / well were plated in a six-well plate coated with poly-lysine and laminin, and the culture plate was shaken back and forth and left and right to disperse the cells evenly; (8) Place the cell culture plate in a cell culture incubator and replace the neuronal differentiation culture medium every 2 days. After 2 weeks, a neuronal cell model is obtained. The differentiated neuronal cell model can be used to detect neuronal differentiation.

[0043] Example 6 Immunofluorescence Identification of Krabbe Disease Neuronal Model (1) Discard the neuronal culture medium in the 12-well plate containing the neuronal cell model in Example 5, wash with PBS three times, add 1 mL of 4% paraformaldehyde and fix at room temperature for 15 min; (2) Discard 4% PFA and wash with PBS three times, 5 min each time; (3) After washing, add 0.5% TritonX-100 and treat at room temperature for 10 min; (4) Add 3% BSA to block at room temperature for 1 h; (5) Primary antibody: Use 1% BSA to prepare the primary antibody working solution (TUJ1, NeuN), then add the primary antibody working solution to the 12-well plate containing the neuronal cell model, and then place it in a humidified box at 4°C overnight; (6) Discard the primary antibody working solution and then wash with PBS three times, 5 min each time; (7) Secondary antibody: Use PBS to dilute the corresponding fluorescent secondary antibody (Anti-Rabbit Alexa Fluor 594, Anti-Mouse Alexa Fluor 488) to prepare the secondary antibody working solution, then add it to the 12-well plate containing the neuronal cell model and place it in a wet box for incubation at room temperature in the dark for 1 hour; (8) Discard the secondary antibody working solution, add an appropriate amount of DAPI dye solution to cover the neuronal cell model, and incubate at room temperature for 5 minutes; (9) Wash three times with PBS, let it dry, add anti-fluorescence quenching mounting medium, cover with a coverslip, and observe under a fluorescence microscope.

[0044] The results are as follows Figure 4 As shown: The expression of Tuj1 and NeuN was positive in neuronal cells, indicating that the iPSCs-derived neuronal cell model of Krabbe patients was successfully constructed.

[0045] Example 7 GALC activity determination The induced neuronal cell model constructed in Example 5 was added with the purified AAV9-CBA-GALC-OPT-Flag recombinant virus in Example 3 at a multiplicity of infection (MOI) of 5×10 5 , infected neurons, and then cultured for 48 hours using MarkerGene TM Lysosomal galactocerebrosidase assay kit (M2774) was used to measure GALC activity. The specific steps are as follows: (1) Take the iPSCs-derived neuronal cell model of Krabbe patients induced successfully in Example 5, add the purified AAV9-CBA-GALC-OPT-Flag recombinant virus in Example 3 for infection experiment, culture for 48 hours, centrifuge at 800 rpm for 5 minutes to collect cells, and adjust the cell density so that the number of cells is >1×10 6 , after centrifugation, discard the supernatant and resuspend the cell pellet in 0.5 mL Lysis Buffer A; (2) placing the lysis buffer A containing cells obtained in step (1) in a cell ultrasonic disruptor, ultrasonicating for 2×30 seconds to obtain a lysate, and then centrifuging the lysate at 27,000×g for 30 minutes to separate the precipitate and the primary supernatant; (3) Resuspend the pellet in 0.5 mL of Lysis Buffer B, and then place it in a cell ultrasonic disruptor for 2 × 30 s for secondary lysis. Then, centrifuge the secondary lysate at 27,000 × g for 30 min and retain the secondary supernatant. (4) The primary supernatant was mixed with the secondary supernatant, and the protein concentration was determined using BCA protein quantification. Based on the protein concentration, the volume required for 50 μg of total protein was calculated, and then the volume was supplemented to 100 μL using Reaction buffer, and added to the substrate reagent tube. The substrate reagent solution was vortexed for 2-3 minutes, and then incubated at 37°C for 2 hours. After 2 hours of reaction, 1 mL of Stop Buffer diluent was added to terminate the reaction, and the resulting protein solution was recorded as the treatment group; the Stop Buffer diluent was diluted by Stop Buffer and anhydrous ethanol in a ratio of 1:1; (5) Blank group: Lysis buffer A and lysis buffer B were mixed in a volume ratio of 1:1, and then placed in a substrate reagent bottle for incubation. The incubation conditions were the same as step (4). After the incubation, 1 mL of the Stop Buffer diluted in step (4) was added to the mixed lysis buffer to obtain a protein solution; (6) Normal group: normal embryonic stem cell line H9 cells were obtained by inducing differentiation to obtain a normal neuronal cell model, and then processed according to the method described in steps (1) to (4) to obtain a protein solution; (7) iPSCs model group: an iPSCs-derived neuronal cell model was obtained and then processed according to the method described in steps (1) to (4) to obtain a protein solution; (8) Use a UVVIS spectrometer to measure the fluorescence readings of the protein solution, model group, normal group, and blank group obtained in step (4). Then, subtract the fluorescence reading of the blank group from the reading of each group of protein solution to record the final fluorescence value of each group of protein solution.

[0046] The results are as follows Figure 5 As shown: the GALC activity in the neuronal cells of the normal group was significantly higher than that in the model group, further indicating that the neuronal cell model constructed in Example 5 can simulate the low GALC enzyme activity state in the cells of Krabbe patients. After AAV9-CBA-GALC-OPT-Flag treatment (treatment group), compared with the iPSCs model group, the GALC activity in the treated Krabbe neuronal cells was significantly improved (GALC-OPT treatment group); it can reach or even exceed that of the normal group, indicating that AAV9-CBA-GALC-OPT-Flag can be used to prepare drugs for the treatment of Krabbe disease.

[0047] Example 8 Psychosine concentration determination Psychosine (Galactosylsphingosine) is a substrate of galactocerebrosidase (GALC) enzyme and a potential biomarker for Krabbe disease. Therefore, detecting Psychosine concentration can help monitor GALC concentration and diagnose Krabbe disease.

[0048] (1) As in Example 7, after the AAV9-CBA-GALC-OPT-Flag recombinant virus infected the neuronal cell model for 48 hours, the cells were collected, 10 mM phosphate buffer (containing 0.1% NP40) was added, and the cells were treated with a Bioprep-24 biological sample homogenizer and a cell ultrasonic disruptor. Then, 100 μg of protein sample was quantitatively obtained from the supernatant, 10 ng of internal standard (D-erythro-Sphingosine) was added, and the mixture was shaken at 4°C for 10 min; (2) Add 4 times the volume (800 μL) of methanol-acetic acid (methanol: acetic acid = 9:1) extract, mix at room temperature for 1 h, centrifuge at 1000 rpm for 10 min, and collect the supernatant; (3) The supernatant was evaporated in a nitrogen blower at 37°C, and then 300 μL of anhydrous methanol was added, resuspended, and centrifuged for 5 min at 13,400 × g and 4°C. (4) After centrifugation, take the supernatant, evaporate it again, add 500 μL of anhydrous methanol, resuspend the sample, and filter it using a 0.22 μm filter membrane to obtain the filtrate; (5) The filtrate obtained in step (4) was used to detect the concentration of psychosine in the solution using an ultra-high performance liquid chromatography triple quadrupole mass spectrometer (1290 Infinity II + 6470B, Agilent) as the treatment group; (6) Model group: the method is the same as steps (1) to (7), except that virus infection is not used; (7) Normal group: The method is the same as steps (1) to (7), except that virus infection is not used, and the neuronal cell model is replaced by growing neuronal cells obtained by induction and differentiation of embryonic stem cell line H9 cells.

[0049] The results are as follows Figure 6 As shown, the concentration of psychosine in the GALC-OPT treatment group was significantly higher than that in the normal group, indicating that the neuronal model constructed in this embodiment can simulate the high psychosine state in Krabbe patient cells. Compared with the iPSCs model group, the concentration of galactosylsphingosine psychosine in the GALC-OPT treatment group was significantly reduced; it can reach the level of the normal group, indicating that AAV9-CBA-GALC-OPT-Flag can effectively reduce the concentration of psychosine and help treat Krabbe disease, indicating that the AAV9-CBA-GALC-OPT-Flag virus is a potential therapeutic drug for Krabbe disease.

Claims

1. A codon-optimized GALC Gene, Features: Said GALC The sequence of the gene is SEQ ID NO:

2.

2. A codon-optimized GALC Gene, Features: Said GALC Gene and wild type GALC The gene sequence has 76% homology; the wild-type GALC gene sequence is SEQ ID NO:

1.

3. A codon-optimized GALC The application of genes in the preparation of drugs for the treatment of Krabbe disease.

4. A codon-optimized GALC Recombinant adeno-associated virus expression vector of gene, Features: Comprising the codon optimized according to claim 1 or 2 GALC Gene and adeno-associated virus expression vector containing CBA promoter.

5. A codon-optimized GALC Recombinant adeno-associated virus expression vector of gene, Features: The sequence of the adeno-associated virus expression vector is SEQ ID NO: 3, and the codon-optimized GALC The gene sequence is SEQ ID NO:

2.

6. A codon-optimized GALC A method for constructing a recombinant adeno-associated virus expression vector for a gene, Features: The steps include: (1) Yes GALC The gene was codon optimized, and a Flag linker was added to the 3' end. After synthesis, the protective base and BamH I / Xho I restriction site were added to the 5' and 3' ends respectively by PCR technology to obtain GALC-OPT-Flag Gene fragments; (2) GALC-OPT-Flag The gene fragment and pAAV-CBA-LUC plasmid were double-digested, recovered and purified, and then ligated with T4 DNA ligase to obtain a ligation product; (3) The ligation product was transformed into Escherichia coli. After overnight culture, a single clone was picked out for amplification and plasmid extraction for detection to obtain the recombinant adeno-associated virus expression vector pAAV-CBA-GALC-OPT-Flag.

7. The construction method according to claim 6, Features: The restriction endonucleases used in the double digestion in step (2) are BamH I and Xho I, and the digestion conditions are 37° C. for 2 h; The connection condition in step (3) is 16° C. for 16 h.

8. A codon-optimized GALC Recombinant adeno-associated virus Features: The recombinant adeno-associated virus comprises an AAV capsid, an AAV genome packaged in the AAV capsid, a CBA promoter, and a codon-optimized GALC Gene sequence; the codon optimized GALC The gene sequence is SEQ ID NO:2, and has 76% homology with the wild-type GALC gene fragment shown in SEQ ID NO:

1.

9. A codon-optimized GALC A method for preparing a recombinant adeno-associated virus containing a gene, Features: The preparation method includes a packaging method and a purification method, wherein the packaging method is to co-transfect HEK 293T cells with pAAV-CBA-GALC-OPT-Flag, pHelper, and pAAV9 using a three-plasmid packaging system, and collect the supernatant and cells after transfection for purification; The purification method is to use iodixanol density gradient centrifugation to purify.

10. A codon-optimized GALC Application of recombinant adeno-associated virus with a gene in the preparation of drugs for treating Krabbe disease.